Why PURE‑HYAL's 1.4% Outperforms Competitors' 1.6%: The Physics of High Molecular Weight Sodium Hyaluronate
A cohesive OVD's real performance comes from chain length, not the number on the label. Here's why a well-formulated 1.4% can out-perform a 1.6% — and where that matters in a cataract case.
What makes an OVD cohesive
Sodium hyaluronate ophthalmic solution is a cohesive OVD used during cataract surgery to maintain anterior chamber depth, protect the corneal endothelium, create working space, and support tissue manipulation during capsulorhexis and IOL implantation.
"Cohesive" describes behavior, not brand: a cohesive OVD's long hyaluronate chains stay entangled with each other, so the material tends to move and aspirate as one connected mass rather than breaking apart — the opposite of a dispersive OVD, which coats and shears into fragments under flow.
Why molecular weight beats concentration
The instinct is to read "1.6%" as automatically higher-performing than "1.4%." That instinct is wrong when formulation quality differs.
Concentration is only half the equation
Viscosity comes from how much hyaluronate is dissolved AND how long and entangled its molecular chains are. Two solutions at the same concentration can behave very differently depending on chain length.
High molecular weight increases entanglement
Longer chains overlap and interact more per unit concentration, producing more resistance to flow — i.e. more viscosity — without needing more material dissolved in the syringe.
The result: lower concentration, higher performance
Through high molecular weight sodium hyaluronate and optimised formulation, PURE‑HYAL 1.4% delivers viscosity that exceeds many 1.6% formulations on the market — while remaining easier to aspirate and remove.
Why easier removal matters
A formulation engineered for high molecular weight rather than brute-force concentration tends to clear the eye more completely at case-close, which is directly relevant to the post-op IOP risk discussed in section 5.
Endothelial protection during phaco
A protective coating
Cohesive sodium hyaluronate forms a protective coating over the corneal endothelium, reducing mechanical and ultrasonic stress during phacoemulsification.
Why this is the default choice
This coating behavior is a core reason cohesive OVDs are the standard choice for endothelial protection in routine cataract cases, ahead of the space-creation role covered next.
Stable anterior chamber through the case
A cohesive OVD's job doesn't end at endothelial protection — it also maintains depth and clarity during capsulorhexis, lens implantation, and IOL positioning, supporting confident surgical manipulation from incision to closure. Smooth injection and efficient cohesive removal support surgical rhythm without unnecessary resistance or residual fragments.
Why cohesive removal matters at case-close
Where cohesive fits vs dispersive
| Property | Cohesive (e.g. PURE‑HYAL) | Dispersive |
|---|---|---|
| Behavior under flow | Moves and aspirates as one mass | Shears and coats in fragments |
| Primary strength | Space creation, chamber stability | Endothelial coating that resists washout |
| Removal | Fast, largely complete on aspiration | Slower, can leave residual coating |
| Typical role | Primary chamber-maintenance agent | Often paired with a cohesive agent (soft-shell) |
Where PURE‑HYAL fits your case
PURE‑HYAL combines high-purity sodium hyaluronate with cohesive viscoelastic behavior for predictable surgical performance — supplied as a 1.4% solution in a glass prefilled syringe. Agaaz's viscoelastic range extends beyond PURE‑HYAL into HPMC-based OP‑VISC and PURE‑VISC for cases where a different viscosity profile is needed.
Add PURE‑HYAL to your cataract range
Specifications, packaging, and export documentation for PURE‑HYAL Sodium Hyaluronate 1.4%.
Frequently asked questions
What is sodium hyaluronate ophthalmic solution used for?
A cohesive OVD used during cataract surgery to maintain anterior chamber depth, protect the corneal endothelium, create working space, facilitate IOL implantation, and support tissue manipulation during capsulorhexis and lens positioning.
How can a 1.4% concentration outperform a 1.6% formulation?
Through high molecular weight sodium hyaluronate and optimised formulation, PURE‑HYAL 1.4% delivers viscosity that exceeds many 1.6% formulations on the market, while remaining easier to aspirate and remove — lower concentration, higher performance.
Why does molecular weight matter more than concentration for a cohesive OVD?
Viscosity comes from chain entanglement, not just how much hyaluronate is in the syringe. Longer chains create more entanglement per unit concentration, so a well-formulated 1.4% can out-perform a lower-quality 1.6% while still clearing more cleanly at case-close.
How does PURE‑HYAL protect the corneal endothelium?
As a cohesive sodium hyaluronate OVD, it forms a protective coating over the endothelium, reducing mechanical and ultrasonic stress during phacoemulsification.
What is cohesive removal and why does it matter?
Cohesive OVDs aspirate out as a single connected mass rather than fragmenting, supporting faster, more complete removal and reducing the chance of residual OVD driving a post-op IOP spike.
Who manufactures PURE‑HYAL?
Agaaz Ophthalmics — an Indian manufacturer and exporter of ophthalmic surgical products including IOLs, viscoelastics, and surgical solutions, supplied in a glass prefilled syringe format.
Quick glossary
- Cohesive OVD
- A viscoelastic that moves and aspirates as one connected mass under flow.
- Dispersive OVD
- A viscoelastic that shears and coats surfaces in fragments under flow.
- Molecular weight
- The average length/mass of the hyaluronate polymer chains in solution — drives entanglement and viscosity independent of concentration.
- Phacoemulsification
- Ultrasonic emulsification and aspiration of the cataractous lens.
- Soft-shell technique
- Layering a dispersive OVD (endothelial coating) beneath a cohesive OVD (space maintenance) in the same case.
- Prefilled syringe (PFS)
- OVD supplied pre-loaded in a sterile syringe, ready for direct injection.
References and further reading
This article is for surgical and clinical education purposes for ophthalmology professionals. It is not a substitute for the product's official prescribing information, institutional protocol, or individual clinical judgment.
Start writing here...
Why PURE-HYAL's 1.4% Outperforms Competitors' 1.6%: The Physics of High Molecular Weight Sodium Hyaluronate